<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04074668</url>
  </required_header>
  <id_info>
    <org_study_id>19-1282</org_study_id>
    <nct_id>NCT04074668</nct_id>
  </id_info>
  <brief_title>Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance</brief_title>
  <acronym>CROCODILE</acronym>
  <official_title>CROCODILE Study: Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado Denver School of Medicine Barbara Davis Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado Denver School of Medicine Barbara Davis Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1 diabetes (T1D) is a complex metabolic disorder with many pathophysiological
      disturbances including insulin resistance (IR) and mitochondrial dysfunction which are
      causally related to the development of diabetic kidney disease (DKD) and which contribute to
      reduced life expectancy. Renal hypoxia, stemming from a potential metabolic mismatch between
      increased renal energy expenditure and impaired substrate utilization, is increasingly
      proposed as a unifying early pathway in the development of DKD. By examining the interplay
      between factors responsible for increased renal adenosine triphosphate (ATP) consumption and
      decreased ATP generation in young adults with and without T1D, this study hopes to identify
      novel therapeutic targets to impede the development of DKD in future trials.

      The investigators propose to address the specific aims in a cross-sectional study with 30
      adults with T1D and 20 controls without a diagnosis of diabetes. For this protocol,
      participants will complete a one day study visit at Children's Hospital Colorado. Patients
      will undergo a Dual-energy X-Ray Absorptiometry (DXA) scan to assess body composition, renal
      Magnetic Resonance Imaging (MRI) to quantify renal oxygenation and perfusion, and a Positron
      Emission Tomography/Computed Tomography (PET/CT) scan to quantify renal O2 consumption. After
      the PET and MRI, participants will undergo a hyperinsulinemic-euglycemic clamp to quantify
      insulin sensitivity. Glomerular Filtration Rate (GFR) and Effective Renal Plasma Flow (ERPF)
      will be measured by iohexol and PAH clearances during the hyperinsulinemic-euglycemic clamp.
      To further investigate the mechanisms of renal damage in T1D, two optional procedures are
      included in the study: 1) kidney biopsy procedure and 2) induction of induced pluripotent
      stem cells (iPSCs) to assess morphometrics and genetic expression of renal tissue.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Renal Oxygenation</measure>
    <time_frame>30 minutes</time_frame>
    <description>Blood oxygen level dependent (BOLD) MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Perfusion</measure>
    <time_frame>30 minutes</time_frame>
    <description>Arterial Spin Labeling (ASL) MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Oxygen Consumption</measure>
    <time_frame>30 minutes</time_frame>
    <description>11-C Acetate PET/CT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>4.5 hours</time_frame>
    <description>Hyperinsulinemic-Euglycemic Clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mitochondrial Function</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for mitochondrial DNA copy number</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mitochondrial Function</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for untargeted metabolite assessment of the tricyclic acid (TCA) cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mitochondrial Function</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for targeted assessment and quantification of glucose oxidation using an established metabolite panel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mitochondrial Function</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for untargeted metabolite assessment of Free Fatty Acid (FFA) oxidation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate (GFR)</measure>
    <time_frame>3 hours</time_frame>
    <description>Iohexol Clearance Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective Renal Plasma Flow (ERPF)</measure>
    <time_frame>2.5 hours</time_frame>
    <description>PAH Clearance Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin-Angiotensin-Aldosterone-System Activity</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for Plasma Renin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin-Angiotensin-Aldosterone-System Activity</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for Angiotensin II levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin-Angiotensin-Aldosterone-System Activity</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for Copeptin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Injury Biomarkers</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for Tyrosine Lysine Leucine-40 (YKL-40) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Injury Biomarkers</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for Neutrophil gelatinase-associated lipocalin (NGAL) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Injury Biomarkers</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for Kidney Injury Marker 1 (KIM-1) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Injury Biomarkers</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for Interleukin-18 (IL-18) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Injury Biomarkers</measure>
    <time_frame>5 minutes</time_frame>
    <description>Blood draw for Tumor Necrosis Factor Receptor 1/2 (TNF-R 1/2) levels</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Podocyte numerical density and number per glomerulus</measure>
    <time_frame>4 hours</time_frame>
    <description>Measured by light microscopy from tissue obtained by renal biopsy</description>
  </other_outcome>
  <other_outcome>
    <measure>Foot process width of glomeruli</measure>
    <time_frame>4 hours</time_frame>
    <description>Measured by electron microscopy from tissue obtained by renal biopsy</description>
  </other_outcome>
  <other_outcome>
    <measure>Detachment and endothelial fenestration of glomeruli</measure>
    <time_frame>4 hours</time_frame>
    <description>Measured by electron microscopy from tissue obtained by renal biopsy</description>
  </other_outcome>
  <other_outcome>
    <measure>Podocyte volume of glomeruli</measure>
    <time_frame>4 hours</time_frame>
    <description>Measured by electron microscopy from tissue obtained by renal biopsy</description>
  </other_outcome>
  <other_outcome>
    <measure>Number and identity of RNA in kidney cells</measure>
    <time_frame>4 hours</time_frame>
    <description>Measured from tissue obtained by renal biopsy</description>
  </other_outcome>
  <other_outcome>
    <measure>Epigenetic profiling</measure>
    <time_frame>4 hours</time_frame>
    <description>Measured from tissue obtained by renal biopsy</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetic Kidney Disease</condition>
  <condition>Type 1 Diabetes</condition>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetes Complications</condition>
  <condition>Diabetic Nephropathies</condition>
  <condition>Type1diabetes</condition>
  <condition>Diabetes, Autoimmune</condition>
  <condition>Autoimmune Diabetes</condition>
  <condition>Juvenile Diabetes</condition>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Type 1 Diabetes</arm_group_label>
    <description>All participants will undergo DXA scan, magnetic resonance imaging (MRI) studies of the kidneys, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>All participants will undergo DXA scan, magnetic resonance imaging (MRI) studies of the kidneys, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminohippurate Sodium Inj 20%</intervention_name>
    <description>Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)</description>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Type 1 Diabetes</arm_group_label>
    <other_name>Sodium 4-amino hippurate (PAH) inj 20% 2 grams (g)/10 milliliters (mL)</other_name>
    <other_name>Para-aminohippurate</other_name>
    <other_name>Aminohippuric acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol Inj 300 milligrams/milliliter (mg/ml)</intervention_name>
    <description>Diagnostic aid/agent used to measure glomerular filtration rate (GFR)</description>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Type 1 Diabetes</arm_group_label>
    <other_name>omnipaque 300</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET/CT Scan</intervention_name>
    <description>Imaging used to visualize the kidneys and quantify renal metabolic activity</description>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Type 1 Diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal Biopsy</intervention_name>
    <description>Minimally invasive outpatient procedure to obtain renal tissue after ultrasound visualization.</description>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Type 1 Diabetes</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      During the study, blood and urine samples will be collected for assessment of kidney function
      and kidney injury markers.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We propose to address the specific aims of this study in a cross-sectional project with 30
        adults with T1D and 20 controls (50% female, ages 18-30 yr).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria -- Type 1 Diabetes:

          -  Antibody positive Type 1 Diabetes with duration &gt; 5 years

          -  BMI between 18.5 and 30 kg/m2

          -  Weight &lt; 350 lbs

          -  HbA1c &lt; 11%

          -  Hemoglobin &gt;= 12 g/dl

        Exclusion Criteria -- Type 1 Diabetes:

          -  Recent diagnosis (within 3 months) of Diabetic Ketoacidosis (DKA)

          -  Severe illness

          -  Pregnancy, nursing

          -  Anemia

          -  Allergy to shellfish or iodine

          -  Claustrophobia or implantable metal devices (MRI contraindications)

          -  High blood pressure (greater than 130/80 mm Hg)

          -  Elevated Urine Albumin-to-Creatinine Ratio (UACR) (&gt;30 mg/g) or estimated Glomerular
             Filtration Rate (eGFR) &lt;90 ml/min/1.73 m2

          -  Taking ACE inhibitors (ACEis), Angiotensin receptor blockers (ARBs), diuretics, Sodium
             Glucose Transporter (SGLT) 1/2 blockers

        Inclusion Criteria -- Healthy Controls:

          -  No diagnosis of Type 1 or Type 2 Diabetes

          -  BMI between 18.5 and 30 kg/m2

          -  Weight &lt; 350 lbs

          -  HbA1c &lt; 11%

          -  Hemoglobin &gt;= 12 g/dl

        Exclusion Criteria -- Healthy Controls:

          -  Severe illness

          -  Pregnancy, nursing

          -  Anemia

          -  Allergy to shellfish or iodine

          -  Claustrophobia or implantable metal devices (MRI contraindications)

          -  High blood pressure (greater than 130/80 mm Hg)

          -  Elevated UACR (&gt;30 mg/g) or eGFR &lt;90 ml/min/1.73 m2

          -  Taking ACE inhibitors (ACEis), Angiotensin receptor blockers (ARBs), diuretics, SGLT
             1/2 blockers

        Additional exclusion criteria for participants undergoing optional kidney biopsy:

          -  Evidence of bleeding disorder or complications from bleeding

          -  Use of aspirin, NSAIDS or other blood thinner that cannot be safely stopped for a
             sufficient time period before and after the biopsy so as to add no additional risk of
             bleeding

          -  Blood urea nitrogen (BUN) &gt; 80 gm/dL

          -  INR &gt; 1.4

          -  PTT &gt; 35 seconds

          -  Hemoglobin (Hgb) &lt; 10 mg/dL

          -  Platelet count &lt; 100,000 / ÂµL

          -  Uncontrolled or difficult to control hypertension (&gt; 150/90 mmHg at the day of biopsy)

          -  eGFR &lt; 40 mL/min/1.73m2

          -  Single kidney (either by history, documented by prior imaging or ultrasound performed
             prior to the biopsy)

          -  &gt; 2 cm discrepancy between left and right kidney sizes based on largest longitudinal
             diameter determined by ultrasound performed prior to the biopsy.

          -  Kidney size: One or both kidneys &lt; 9 cm

          -  Hydronephrosis or other important renal ultrasound findings such as significant stone
             disease

          -  Any evidence of a current urinary tract infection as indicated on day of biopsy

          -  Clinical evidence of non-diabetic renal disease

          -  Positive urine pregnancy test or pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carissa Vinovskis, MS</last_name>
    <phone>720-777-2660</phone>
    <email>carissa.vinovskis@childrenscolorado.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Petter Bjornstad, MD</last_name>
    <phone>720-777-4659</phone>
    <email>petter.bjornstad@childrenscolorado.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petter Bjornstad, MD</last_name>
      <phone>720-777-4659</phone>
      <email>petter.bjornstad@childrenscolorado.org</email>
    </contact>
    <contact_backup>
      <last_name>Carissa Vinovskis, MS</last_name>
      <phone>720-777-2660</phone>
      <email>carissa.vinovskis@childrenscolorado.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Colorado Denver School of Medicine Barbara Davis Center</investigator_affiliation>
    <investigator_full_name>Petter Bjornstad</investigator_full_name>
    <investigator_title>Asisstant Professor of Medicine and Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

